STOCKWATCH
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Quarterly ResultMay 13, 2026, 04:22 PM

Precision Optics Raises $10.6M in Public Offering; Q3 Revenue +108%

AI Summary

Precision Optics Corporation, Inc. completed a public offering, raising $10.6 million in net proceeds by issuing 3,194,444 shares. For the three months ended March 31, 2026, the company reported a significant revenue increase of 108% to $8.7 million and substantially reduced its net loss by 95% to $0.1 million. Over the nine-month period, revenues grew 76% to $22.8 million, with a 19% reduction in net loss to $3.5 million.

Key Highlights

  • Public offering of 3,194,444 shares generated $10,630,678 in net proceeds.
  • Q3 2026 revenue increased 108% to $8,708,631 from $4,185,968 in Q3 2025.
  • Q3 2026 net loss significantly reduced by 95% to $(108,283) from $(2,096,761) in Q3 2025.
  • Nine-month revenue grew 76% to $22,757,291 from $12,909,928 in prior year.
  • Nine-month net loss reduced by 19% to $(3,526,104) from $(4,377,689) in prior year.
  • Cash and cash equivalents rose to $10,680,046 at March 31, 2026, from $1,773,735 at June 30, 2025.
  • Systems Manufacturing revenue for Q3 2026 surged to $6,188,594 from $2,019,596.
  • Total assets increased to $33,686,207 at March 31, 2026, from $19,790,287 at June 30, 2025.
POCI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
PRECISION OPTICS CORPORATION, INC.

Price Impact